Detailed Narrative
Strong Q2 FY26 Financial Performance
Thyrocare Technologies delivered a robust Q2 FY26, with consolidated revenue reaching an all-time high of ₹217 crores, marking a 22% year-on-year growth. Standalone revenue also hit a record close to ₹200 crores, growing 24% YoY. Profitability saw significant improvement, with consolidated normalized EBITDA margin at 34.8% (up 49% YoY) and PAT growing 82% YoY, leading to an EPS of ₹9.05 for the quarter, up from ₹4.99 last year.
Franchisee and Partnership Business Driving Growth
The company's growth was primarily fueled by its core businesses, with the franchisee segment reporting a 20% YoY revenue increase and the partnerships business demonstrating a 'tremendous growth' of 35%. The API PharmEasy Diagnostics business also grew significantly by 46% YoY. Thyrocare expanded its active quarterly franchisee base to over 10,100, up from 8,446 in the same quarter last year, consistently adding 100-150 net franchisees monthly.
Enhanced Operational Efficiency and Quality Initiatives
Thyrocare achieved 100% NABL accreditation across all its national labs, becoming India's first. The company has set an ambitious target to achieve Six Sigma level quality, aiming to reduce complaints per million below 3.4, a significant improvement from 11.8% in Q2 FY25 to 3.8% this quarter. Turnaround time for reports improved to within 3.52 hours on average after samples reached the lab, with overall pan-India TAT now less than 18 hours, down from over 40 hours previously.
Strategic Investments and Market Expansion
The company continues to expand its test menu, with Aarogyam (preventive healthcare) growing 19% YoY and Jaanch (lifestyle/chronic health) growing 31% YoY. Strategic investments include a robust cold chain logistics with data loggers for end-to-end tracking and expansion of its lab network, which currently stands at 37 labs in India and 1 in Tanzania. The Tanzania business grew 30% QoQ and is expected to double revenues this year, aiming for operating breakeven in 18-24 months.
Emerging Opportunity in GLP-1 Diagnostics
Management identified a 'huge opportunity' in diagnostics related to GLP-1 weight loss drugs, with plans to launch complementary testing packages (pre, during, and post-therapy). While current volume growth is in the mid-teens, the company anticipates 'much higher' volume growth in coming quarters (FY27, FY28) from this segment. However, specific guidance is reserved for later due to the early stage of this market and competitive sensitivities.
Shareholder Returns and Capital Allocation
In addition to strong financial performance, the Board approved a 2:1 bonus issue from free reserves and declared an interim dividend of ₹7 per equity share (pre-bonus), with a record date of October 24, 2025. The company remains debt-free with over ₹190 crores in net cash and cash equivalents, including short-term mutual funds, indicating a strong balance sheet and capacity for future investments and shareholder returns.
Segmental Performance and Outlook
The Pathology business grew 24% YoY, while fever-related volumes were down 26% YoY due to government efforts to control viral vectors. The Radiology active sector showed marginal growth of 3%, with management focusing on profitable growth after the segment was loss-making last year. Q3 is expected to be seasonally soft for margins, with a recovery anticipated in Q4, and H1 to H2 margins are projected to be similar unless significant investment opportunities arise.